Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

Similar articles for PubMed (Select 23752739)

1.

Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy.

Benhaim L, Gerger A, Bohanes P, Paez D, Wakatsuki T, Yang D, Labonte MJ, Ning Y, El-Khoueiry R, Loupakis F, Zhang W, Laurent-Puig P, Lenz HJ.

Pharmacogenomics J. 2014 Apr;14(2):135-41. doi: 10.1038/tpj.2013.21. Epub 2013 Jun 11.

PMID:
23752739
2.

Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy.

Ning Y, Gerger A, Zhang W, Hanna DL, Yang D, Winder T, Wakatsuki T, Labonte MJ, Stintzing S, Volz N, Sunakawa Y, Stremitzer S, El-Khoueiry R, Lenz HJ.

Mol Cancer Ther. 2014 Feb;13(2):528-39. doi: 10.1158/1535-7163.MCT-13-0646. Epub 2013 Oct 29.

3.

The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy.

Absenger G, Benhaim L, Szkandera J, Zhang W, Yang D, Labonte MJ, Pichler M, Stotz M, Samonigg H, Renner W, Gerger A, Lenz HJ.

Pharmacogenomics J. 2014 Apr;14(2):130-4. doi: 10.1038/tpj.2013.15. Epub 2013 Apr 9.

PMID:
23567490
4.

DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ.

J Natl Cancer Inst. 2011 Jun 8;103(11):863-75. doi: 10.1093/jnci/djr153. Epub 2011 May 19. Erratum in: J Natl Cancer Inst. 2011 Nov 2;103(21):1639. Kim, George P [added].

5.

5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.

Jover R, Nguyen TP, Pérez-Carbonell L, Zapater P, Payá A, Alenda C, Rojas E, Cubiella J, Balaguer F, Morillas JD, Clofent J, Bujanda L, Reñé JM, Bessa X, Xicola RM, Nicolás-Pérez D, Castells A, Andreu M, Llor X, Boland CR, Goel A.

Gastroenterology. 2011 Apr;140(4):1174-81. doi: 10.1053/j.gastro.2010.12.035. Epub 2010 Dec 24.

6.

GOLPH3 predicts survival of colorectal cancer patients treated with 5-fluorouracil-based adjuvant chemotherapy.

Wang Z, Jiang B, Chen L, Di J, Cui M, Liu M, Ma Y, Yang H, Xing J, Zhang C, Yao Z, Zhang N, Dong B, Ji J, Su X.

J Transl Med. 2014 Jan 21;12:15. doi: 10.1186/1479-5876-12-15.

7.

Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.

Gordon MA, Zhang W, Yang D, Iqbal S, El-Khouiery A, Nagashima F, Lurje G, Labonte M, Wilson P, Sherrod A, Ladner RD, Lenz HJ.

Pharmacogenomics. 2011 Jan;12(1):27-39. doi: 10.2217/pgs.10.163.

8.

Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy.

Lai CY, Sung FC, Hsieh LL, Tang R, Chiou HY, Wu FY, Yeh CC.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S599-606. doi: 10.1245/s10434-013-3069-4. Epub 2013 Jun 26.

PMID:
23800895
9.

Genetic variations in the HIF1A gene modulate response to adjuvant chemotherapy after surgery in patients with colorectal cancer.

Zhang Y, Wang P, Zhou XC, Bao GQ, Lyu ZM, Liu XN, Wan SG, He XL, Huang QC.

Asian Pac J Cancer Prev. 2014;15(11):4637-42.

10.
11.

[Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].

Kralovánszky J, Adleff V, Hitre E, Pap E, Réti A, Komlósi V, Budai B.

Magy Onkol. 2007;51(2):113-25. Epub 2007 Jul 29. Hungarian.

12.

DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy.

Liu D, Wu HZ, Zhang YN, Kang H, Sun MJ, Wang EH, Yang XL, Lian MQ, Yu ZJ, Zhao L, Olopade OI, Wei MJ.

Mol Carcinog. 2012 Oct;51 Suppl 1:E83-93. doi: 10.1002/mc.21862. Epub 2011 Dec 27.

PMID:
22213216
13.

Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.

McCleary NJ, Meyerhardt JA, Green E, Yothers G, de Gramont A, Van Cutsem E, O'Connell M, Twelves CJ, Saltz LB, Haller DG, Sargent DJ.

J Clin Oncol. 2013 Jul 10;31(20):2600-6. doi: 10.1200/JCO.2013.49.6638. Epub 2013 Jun 3.

14.

Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.

Soong R, Shah N, Salto-Tellez M, Tai BC, Soo RA, Han HC, Ng SS, Tan WL, Zeps N, Joseph D, Diasio RB, Iacopetta B.

Ann Oncol. 2008 May;19(5):915-9. doi: 10.1093/annonc/mdm599. Epub 2008 Feb 1.

15.

A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.

Chau I, Norman AR, Cunningham D, Tait D, Ross PJ, Iveson T, Hill M, Hickish T, Lofts F, Jodrell D, Webb A, Oates JR.

Ann Oncol. 2005 Apr;16(4):549-57. Epub 2005 Feb 2.

16.

MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer.

Afzal S, Jensen SA, Vainer B, Vogel U, Matsen JP, Sørensen JB, Andersen PK, Poulsen HE.

Ann Oncol. 2009 Oct;20(10):1660-6. doi: 10.1093/annonc/mdp046. Epub 2009 May 22.

17.

Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.

Chen SP, Wu CC, Lin SZ, Kang JC, Su CC, Chen YL, Lin PC, Chiu SC, Pang CY, Harn HJ.

Am J Clin Oncol. 2009 Apr;32(2):122-6. doi: 10.1097/COC.0b013e318181f959.

PMID:
19307944
18.

Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma.

Lin M, Eng C, Hawk ET, Huang M, Lin J, Gu J, Ellis LM, Wu X.

Cancer. 2012 Dec 15;118(24):6188-98. doi: 10.1002/cncr.27653. Epub 2012 Jun 6.

19.
20.

Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.

Hemminki A, Mecklin JP, Järvinen H, Aaltonen LA, Joensuu H.

Gastroenterology. 2000 Oct;119(4):921-8.

PMID:
11040179
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk